Theriva Biologics, Inc.TOVXNYSE
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+187.5%
5Y CAGR+20.0%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+187.5%/yr
vs -9.5%/yr prior
5Y CAGR
+20.0%/yr
Recent acceleration
Acceleration
+197.0pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 76.68% |
| Q2 2025 | -24.52% |
| Q1 2025 | 63.62% |
| Q4 2024 | 37.44% |
| Q3 2024 | 36.65% |
| Q2 2024 | -42.76% |
| Q1 2024 | 5.87% |
| Q4 2023 | -64.95% |
| Q3 2023 | 42.12% |
| Q2 2023 | -13.24% |
| Q1 2023 | 16.76% |
| Q4 2022 | -2863.33% |
| Q3 2022 | 3.23% |
| Q2 2022 | 0.00% |
| Q1 2022 | 22.50% |
| Q4 2021 | -60.00% |
| Q3 2021 | -4.17% |
| Q2 2021 | 14.29% |
| Q1 2021 | 72.00% |
| Q4 2020 | 7.41% |
| Q3 2020 | 30.77% |
| Q2 2020 | 9.83% |
| Q1 2020 | 7.49% |
| Q4 2019 | 38.69% |
| Q3 2019 | -42.52% |
| Q2 2019 | 4.46% |
| Q1 2019 | -9.27% |
| Q4 2018 | 77.57% |
| Q3 2018 | 19.75% |
| Q2 2018 | -80.79% |
| Q1 2018 | -181.82% |
| Q4 2017 | 125.84% |
| Q3 2017 | -146.08% |
| Q2 2017 | -42.81% |
| Q1 2017 | -6.00% |
| Q4 2016 | 74.98% |
| Q3 2016 | -46.32% |
| Q2 2016 | 47.71% |
| Q1 2016 | 1.16% |
| Q4 2015 | -53.30% |